Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 10/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 8/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12634777 | 0.87 | ADRB2 (0.43) | ADRB2HTR1APCSK9SYKKCNA5 | |
| SCHEMBL12634765 | 0.87 | ADRB2 (0.43) | ADRB2HTR1APCSK9SYKKCNA5 | |
| SCHEMBL3303039 | 0.86 | ADRB2 (0.51) | ADRB2HTR1AADRB1 | |
| SCHEMBL12667207 | 0.85 | ADRB2 (0.42) | ADRB2HTR1ASYKKCNA5SCN9A | |
| SCHEMBL12668163 | 0.85 | ADRB2 (0.42) | ADRB2HTR1ASYKKCNA5SCN9A | |
| SCHEMBL14092185 | 0.84 | PCSK9 (0.46) | ADRB2HTR1APCSK9SYKCPB2 | |
| SCHEMBL7259200 | 0.83 | KCNA5 (0.46) | ADRB2HTR1AKCNA5SCN9A | |
| SCHEMBL14047146 | 0.83 | PCSK9 (0.48) | ADRB2HTR1APCSK9SYKCPB2 | |
| SCHEMBL6874085 | 0.81 | NQO2 (0.51) | ADRB2HTR1AADRB1SCN9A | |
| SCHEMBL18052209 | 0.80 | PCSK9 (0.48) | ADRB2HTR1APCSK9SYKCPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2316846-B1 | Spatially-defined macrocyclic compounds useful for drug discovery | OCERA THERAPEUTICS INC (US) | 2019-10-02 | — | — | EP | disclosed |
| US-9181298-B2 | Intermediates for macrocyclic compounds | OCERA THERAPEUTICS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-8497242-B2 | Processes for intermediates for macrocyclic compounds | TRANZYME PHARMA INC. (CA) | 2013-07-30 | — | — | US | disclosed |
| US-20120226066-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-09-06 | — | — | US | disclosed |
| US-20120226072-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-09-06 | — | — | US | disclosed |
| US-20120226067-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-09-06 | — | — | US | disclosed |
| US-20120165566-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-06-28 | — | — | US | disclosed |
| US-8129561-B2 | Processes for intermediates for macrocyclic compounds | TRANZYME PHARMA INC. (CA) | 2012-03-06 | — | — | US | disclosed |
| US-20110245459-A1 | Processes for Intermediates for Macrocyclic Compounds | IMC EXPLORATION COMPANY | 2011-10-06 | — | — | US | disclosed |
| EP-1648922-B1 | SPATIALLY-DEFINED MACROCYCLIC COMPOUNDS USEFUL FOR DRUG DISCOVERY | TRANZYME PHARMA INC (CA) | 2010-12-01 | — | — | EP | disclosed |
| EP-1633774-B1 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR | TRANZYME PHARMA INC (CA) | 2010-02-17 | — | — | EP | disclosed |
| US-20090240027-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | TRANZYME PHARMA INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090137835-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | TRANZYME PHARMA INC. | 2009-05-28 | — | — | US | disclosed |
| US-7521420-B2 | Macrocyclic antagonists of the motilin receptor | TRANZYME PHARMA, INC. (CA) | 2009-04-21 | — | — | US | disclosed |
| US-7452862-B2 | Conformationally-controlled biologically active macrocyclic small molecules as motilin antagonists or ghrelin agonists | TRANZYME PHARMA, INC. (CA) | 2008-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137835-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | ADRB2 488/4885HTR1A 124/4885PCSK9 1770/4885 |
| US-20120165566-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | ADRB2 488/4885HTR1A 124/4885PCSK9 1770/4885 |
| US-20110245459-A1 | Processes for Intermediates for Macrocyclic Compounds | MLNR, CHRM2, CHRM1 | ADRB2 488/4885HTR1A 124/4885PCSK9 1770/4885 |
| US-20120226066-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | ADRB2 488/4885HTR1A 124/4885PCSK9 1770/4885 |
| US-20090240027-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CCKAR, CHRM2 | ADRB2 457/4885HTR1A 128/4885PCSK9 1685/4885 |
| US-20120226067-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CCKAR | ADRB2 437/4885HTR1A 115/4885PCSK9 1791/4885 |
| US-20120226072-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | ADRB2 488/4885HTR1A 124/4885PCSK9 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.